Please login to the form below

Not currently logged in
Email:
Password:

Sepracor signs EU marketing deal with GSK

Sepracor signs an agreement to market its sleep drug Lunivia with GSK in the EU

US-headquartered drug development company Sepracor has signed an agreement to market its sleep drug Lunivia (eszopiclone) in the EU with UK-based pharmaceutical company, GlaxoSmithKline (GSK).

Lunivia is currently under market review in the region, but has been commercially available in the US as Lunesta since 2005 to treat insomnia. Per the agreement, the drug will be marketed by GSK everywhere, except the US, Canada, Japan and Mexico.

Sepracor will receive an initial payment of USD 20m from GSK and is entitled to USD 155m in license and milestone payments, as well as double-digit royalties which would escalate upon increased product sales, says the firm.

In FY06, US product sales were about USD 566.8m, while the EU sedative hypnotic market was estimated to be worth about USD 500m in 2006.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics